Security
NextCure, Inc. Common Stock · NXTC
NXTCNASDAQCommon stockCurrentCIK 1661059Updated Nov 1, 2026
NXTC price & chart
Loading TradingView…
NASDAQ:NXTC on TradingView ↗About the company
NextCure is a biopharmaceutical company headquartered in Beltsville, Maryland. NextCure's retained clinical, regulatory, CMC, and finance personnel support the ongoing clinical development of LNCB74 under the Company's Transition and Continuation Agreement with LigaChem Biosciences, manage the transition of patients enrolled in the SIM0505 study, and conduct the Company's efforts to partner, license or otherwise monetize its legacy clinical and preclinical assets. NextCure has entered into a definitive merger agreement with Avere Therapeutics and, upon closing, the combined company is expected to operate as Avere Therapeutics and to be listed on Nasdaq under the ticker symbol “AVRX.”
In the news
Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders ↗
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers ↗
Seeking Alpha
NextCure announces reverse merger with privately held Avere ↗
NextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma Transcript ↗
NextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma - Slideshow ↗
SEC disclosures
NextCure, Inc. files merger communication (425) ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 39,613,000Source | 90,345,000Source | 22,620,000Source | 47,689,000Source | 102,589,000Source | 37,977,000Source | 67,137,000Source | 115,159,000Source | 50,183,000Source | 80,860,000Source | 128,038,000Source | 184,161,000Source |
| Property, Plant and Equipment, NetUSD | 3,638,000Source | 6,167,000Source | 283,000Source | 4,171,000Source | 6,699,000Source | 2,990,000Source | 4,804,000Source | 7,097,000Source | 3,273,000Source | 5,458,000Source | 9,033,000Source | 11,897,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 7,324,000Source | 27,702,000Source | 15,260,000Source | 4,892,000Source | 20,848,000Source | 15,167,000Source | 21,827,000Source | 18,358,000Source | 25,982,000Source | 27,727,000Source | 13,082,000Source | 26,630,000Source |
| Assets, CurrentUSD | 32,640,000Source | 78,693,000Source | 22,255,000Source | 40,015,000Source | 90,455,000Source | 31,741,000Source | 58,897,000Source | 102,552,000Source | 43,747,000Source | 71,807,000Source | 112,725,000Source | 163,983,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,530,000Source | 3,385,000Source | 2,167,000Source | 4,707,000Source | 4,019,000Source | 1,998,000Source | 3,037,000Source | 6,551,000Source | 1,929,000Source | 3,186,000Source | 4,426,000Source | 4,072,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,785,000Source | 3,415,000Source | — | 2,948,000Source | 3,561,000Source | 2,399,000Source | 3,108,000Source | 3,632,000Source | 2,617,000Source | 3,263,000Source | 4,398,000Source | 5,016,000Source |
| Other Assets, NoncurrentUSD | 550,000Source | 2,070,000Source | 82,000Source | 555,000Source | 1,874,000Source | 847,000Source | 328,000Source | 1,878,000Source | 546,000Source | 332,000Source | 1,882,000Source | 3,265,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 15,967,000Source | 14,753,000Source | 10,471,000Source | 16,043,000Source | 17,148,000Source | 11,261,000Source | 11,282,000Source | 16,111,000Source | 15,240,000Source | 15,388,000Source | 13,617,000Source | 16,631,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 3,000Source | 28,000Source | 4,000Source | 2,000Source | 28,000Source | 4,000Source | 28,000Source | 28,000Source | 4,000Source | 28,000Source | 28,000Source | 28,000Source |
| Additional Paid in CapitalUSD | 450,170,000Source | 444,021,000Source | 472,816,000Source | 447,571,000Source | 442,492,000Source | 472,490,000Source | 446,939,000Source | 440,791,000Source | 470,898,000Source | 445,576,000Source | 439,097,000Source | 430,755,000Source |
| Retained Earnings (Accumulated Deficit)USD | -426,544,000Source | -368,533,000Source | -460,668,000Source | -417,920,000Source | -356,993,000Source | -445,776,000Source | -391,112,000Source | -341,589,000Source | -435,980,000Source | -380,136,000Source | -324,482,000Source | -261,759,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 17,000Source | 76,000Source | -3,000Source | -7,000Source | -86,000Source | -2,000Source | — | -182,000Source | 21,000Source | 4,000Source | -222,000Source | -1,494,000Source |
| Stockholders' Equity Attributable to ParentUSD | 23,646,000Source | 75,592,000Source | 12,149,000Source | 29,646,000Source | 85,441,000Source | 26,716,000Source | 55,855,000Source | 99,048,000Source | 34,943,000Source | 65,472,000Source | 114,421,000Source | 167,530,000Source |
| Liabilities and EquityUSD | 39,613,000Source | 90,345,000Source | 22,620,000Source | 47,689,000Source | 102,589,000Source | 37,977,000Source | 67,137,000Source | 115,159,000Source | 50,183,000Source | 80,860,000Source | 128,038,000Source | 184,161,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 10,995,000Source | 8,672,000Source | 6,413,000Source | 10,781,000Source | 10,833,000Source | 6,891,000Source | 5,740,000Source | 9,583,000Source | 10,566,000Source | 9,574,000Source | 6,883,000Source | 9,127,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | — | — | — | — | 1,005,000Source | 796,000Source | 656,000Source | 518,000Source |
| Accounts Payable, CurrentUSD | 2,391,000Source | 3,613,000Source | 2,578,000Source | 2,544,000Source | 5,075,000Source | 3,070,000Source | 2,736,000Source | 4,491,000Source | 2,011,000Source | 5,353,000Source | 2,330,000Source | 4,270,000Source |
| Operating Lease, Liability, NoncurrentUSD | 4,411,000Source | 5,388,000Source | 3,603,000Source | 4,666,000Source | 5,590,000Source | 3,879,000Source | 4,913,000Source | 5,773,000Source | 4,148,000Source | 5,153,000Source | 5,949,000Source | 6,605,000Source |
| Other Liabilities, NoncurrentUSD | 561,000Source | 693,000Source | 455,000Source | 596,000Source | 725,000Source | 491,000Source | 629,000Source | 755,000Source | 526,000Source | 661,000Source | 785,000Source | 899,000Source |
| Additional Financial Items | ||||||||||||
| Long-term DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -9,796,000Source | -10,976,000Source | -55,844,000Source | -55,654,000Source | -62,723,000Source | -74,733,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | — | 2,200,000Source | 2,900,000Source | 3,700,000Source | 4,100,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 344,000Source | 1,363,000Source | 2,986,000Source | 6,335,000Source | 8,188,000Source | 9,508,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 1,059,000Source | -2,617,000Source | -3,342,000Source | 3,023,000Source | -1,940,000Source | 2,328,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -13,363,000Source | -12,994,000Source | -49,613,000Source | -40,805,000Source | -52,974,000Source | -53,886,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 1,300,000Source | 7,094,000Source | 25,556,000Source | 55,306,000Source | 39,272,000Source | 67,979,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | 474,000Source | 820,000Source | 2,116,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 1,248,000Source | — | 22,312,000Source | 144,000Source | 154,000Source | 200,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -10,815,000Source | -5,900,000Source | -1,745,000Source | 14,645,000Source | -13,548,000Source | 14,293,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 7,324,000Source | 27,701,000Source | 15,260,000Source | 4,892,000Source | 15,167,000Source | 21,827,000Source | 25,982,000Source | 27,727,000Source | 13,082,000Source | 26,630,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 14,000Source | 16,000Source | 62,000Source | 72,000Source | 81,000Source | 90,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 600,000Source | 1,529,000Source | 304,000Source | 587,000Source | 344,000Source | 1,363,000Source | 2,986,000Source | 6,335,000Source | 8,188,000Source | 9,508,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | -87,000Source |
| General and Administrative ExpenseUSD | — | — | 2,809,000Source | 3,725,000Source | 2,592,000Source | 3,201,000Source | 3,271,000Source | 3,726,000Source | 12,693,000Source | 15,718,000Source | 19,706,000Source | 21,710,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -8,624,000Source | -11,540,000Source | -14,892,000Source | -26,808,000Source | -9,796,000Source | -10,976,000Source | -55,844,000Source | -55,654,000Source | -62,723,000Source | -74,733,000Source |
| Operating ExpensesUSD | — | — | 8,945,000Source | 12,495,000Source | 15,094,000Source | 27,292,000Source | 10,105,000Source | 11,622,000Source | 57,616,000Source | 59,748,000Source | 67,637,000Source | 75,909,000Source |
| Operating Lease, ExpenseUSD | — | — | 251,000Source | 253,000Source | 249,000Source | 252,000Source | 250,000Source | 252,000Source | 1,000,000Source | 1,000,000Source | 1,100,000Source | 1,000,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 321,000Source | 955,000Source | 202,000Source | 484,000Source | 309,000Source | 646,000Source | 1,772,000Source | 4,094,000Source | 4,914,000Source | 1,176,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 1,234,000Source | — | — | 39,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 14,000Source | — | — | 23,000Source | 5,000Source | 66,000Source |
| Restructuring Costs and Asset Impairment ChargesUSD | — | — | — | — | 5,077,000Source | — | — | — | — | 2,542,000Source | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -8,945,000Source | -12,495,000Source | -15,094,000Source | -27,292,000Source | -10,105,000Source | -11,622,000Source | -57,616,000Source | -59,748,000Source | -67,637,000Source | -75,909,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 321,000Source | 955,000Source | 202,000Source | 484,000Source | 309,000Source | 646,000Source | 1,772,000Source | 4,094,000Source | 4,914,000Source | 1,176,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -8,624,000Source | -11,540,000Source | -14,892,000Source | -26,808,000Source | -9,796,000Source | -10,976,000Source | -55,844,000Source | -55,654,000Source | -62,723,000Source | -74,733,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -3.22Source | -4.95Source | -2.8Source | -11.29Source | -1.87Source | -4.7Source | -19.65Source | -1.99Source | -2.25Source | -2.69Source |
| Earnings Per Share, DilutedUSD per share | — | — | -3.22Source | -4.95Source | -2.8Source | -11.29Source | -1.87Source | -4.7Source | -19.65Source | -1.99Source | -2.25Source | -2.69Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 2,676,116Source | 2,331,320Source | 5,309,724Source | 2,374,729Source | 5,239,236Source | 2,333,890Source | 2,842,448Source | 27,964,639Source | 27,836,584Source | 27,744,209Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 2,676,116Source | 2,331,320Source | 5,309,724Source | 2,374,729Source | 5,239,236Source | 2,333,890Source | 2,842,448Source | 27,964,639Source | 27,836,584Source | 27,744,209Source |
| Additional Financial Items | ||||||||||||
| Common Stock, Dividends, Per Share, DeclaredUSD per share | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 2,809,000Source | 3,725,000Source | 2,592,000Source | 3,201,000Source | 3,271,000Source | 3,726,000Source | 12,693,000Source | 15,718,000Source | 19,706,000Source | 21,710,000Source |
| Operating ExpensesUSD | — | — | 8,945,000Source | 12,495,000Source | 15,094,000Source | 27,292,000Source | 10,105,000Source | 11,622,000Source | 57,616,000Source | 59,748,000Source | 67,637,000Source | 75,909,000Source |
| Operating Lease, ExpenseUSD | — | — | 251,000Source | 253,000Source | 249,000Source | 252,000Source | 250,000Source | 252,000Source | 1,000,000Source | 1,000,000Source | 1,100,000Source | 1,000,000Source |
| Research and Development ExpenseUSD | — | — | 6,136,000Source | 8,770,000Source | 7,425,000Source | 24,091,000Source | 6,834,000Source | 7,896,000Source | 44,923,000Source | 41,488,000Source | 47,931,000Source | 54,199,000Source |
Offerings
Registration 333-298424
Filing attachments
nxtc-20260915xex99d1.htm · 425 · 2026-09-25
Exhibit 99.1 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE NEXTCURE, INC. ) C.A. No. 2026-____-_____ ) ) ────────────────────────────────────────────────────────────── verified petition for relief pursuant to 8 del. c. § 205 Petitioner NextCure, Inc. (“NextCure” or the “Company”), by and through its undersigned counsel, brings this petition pursuant to 8 Del. C. § 205, seeking to have this Court validate a po…
Read attachment ↗nxtc-20260921xex99d1.htm · 8-K · 2026-09-25
Exhibit 99.1 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE NEXTCURE, INC. ) C.A. No. 2026-____-_____ ) ) ────────────────────────────────────────────────────────────── verified petition for relief pursuant to 8 del. c. § 205 Petitioner NextCure, Inc. (“NextCure” or the “Company”), by and through its undersigned counsel, brings this petition pursuant to 8 Del. C. § 205, seeking to have this Court validate a po…
Read attachment ↗nxtc-20260806xex99d1.htm · 8-K · 2026-08-06
EX-99.1 2 nxtc-20260806xex99d1.htm EX-99.1 Exhibit 99.1 NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results Announced Proposed Merger with Avere Therapeutics Preserving Capital in Support of Merger Closing; Continuing Clinical Transition and Legacy Asset Activities BELTSVILLE, MD - August 6, 2026 (GLOBE NEWSWIRE) - NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat…
Read attachment ↗tm2620428d1_ex99-1.htm · 425 · 2026-07-14
Exhibit 99.1 NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy Avere Therapeutics’ lead program, AVR-001, is a differentiated oral peptide interleukin-23 (IL-23) receptor antagonist, with Phase 1b psoriasis data supporting its potential to be rapidly developed as a convenient, once-weekly oral therapy Concurrent $320 million private investment from world-class investor syndicate ensures combined company is well-capitalized to accelerate development of A…
Read attachment ↗tm2620428d1_ex99-1.htm · 8-K · 2026-07-14
EX-99.1 9 tm2620428d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy Avere Therapeutics’ lead program, AVR-001, is a differentiated oral peptide interleukin-23 (IL-23) receptor antagonist, with Phase 1b psoriasis data supporting its potential to be rapidly developed as a convenient, once-weekly oral therapy Concurrent $320 million private investment from world-class investor syndicate ensures combined company …
Read attachment ↗nxtc-20260601xex99d1.htm · 8-K · 2026-06-01
EX-99.1 2 nxtc-20260601xex99d1.htm EX-99.1 Exhibit 99.1 NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026 55% ORR in gynecologic cancers with 52.9% in ovarian and 66.7% in USC at 12 weeks by best response per RECIST 1.1 within the therapeutic dose range (4.8 – 8.0 mg/kg) Favorable safety and tolerability in heavily pretreated population supports ongoing Phase 1 dose-optimization with emphasis on PROC NextCure to host v…
Read attachment ↗